Comments
Natco Pharma has announced the launch of the first generic version of Nexavar (Sorafenib) tablets in the US market on Wednesday.
The product will be launched by Hyderabad-based Natco Pharma’s commercial partner, Viatris, a global pharmaceutical company.
Sorafenib is prescribed for the treatment of unresectable hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC).
Nexavar registered sales of $ 69.7 million for the year ending December 2021 as per industry sales data. Nexavar is a registered trademark of Bayer Healthcare Pharmaceuticals Inc, according to a release.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.